Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7509877 | 0.86 | HTT (0.60) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL1568467 | 0.86 | HTT (0.59) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL8913074 | 0.85 | CTSL (0.69) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL17814806 | 0.84 | FOLH1 (0.55) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL5217172 | 0.83 | HTT (0.68) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL127662 | 0.83 | HTT (0.82) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL3295121 | 0.82 | HTT (0.62) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL17846625 | 0.82 | LMNA (0.61) | HTTLMNASMN1; SMN2CTSLCTSB | |
| SCHEMBL13055383 | 0.82 | LMNA (0.80) | HTTLMNASMN1; SMN2L3MBTL1MEN1 | |
| SCHEMBL19763216 | 0.82 | LMNA (0.65) | HTTLMNASMN1; SMN2CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352659-A1 | SELF-STABILIZING LINKER CONJUGATES | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| US-12145913-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| CN-115215807-A | Inhibition of OLIG2 activity | 科泰纳制药公司 | 2022-10-21 | — | — | CN | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| WO-2018039621-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. (US) | 2018-03-01 | — | — | WO | disclosed |
| EP-2157091-B1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2013-07-04 | — | — | US | disclosed |
| US-8404684-B2 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| EP-2157091-A1 | Inhibitors of phosphatidylinositol 3-kinase | Novartis AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| EP-1622897-B1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | NOVARTIS AG (CH) | 2007-02-08 | — | — | US | disclosed |
| EP-1622897-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096797-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-6720346-B2 | (4-AMINOTHIAZOL-2-YLAMINO)-BENZAMIDE COMPOUNDS; PROTEIN KINASE INHIBITORS; CANCER; AUTOIMMUNE, VIRAL, FUNGAL, NEURODEGENERATIVE, AND CARDIOVASCULAR DISORDERS | AGOURON PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| US-5607960-A | Indole derivatives as 5-HT1-like agonists for use in migraine | PFIZER INC. (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0695301-A1 | INDOLE DERIVATIVES AS 5-H1-LIKE AGONISTS FOR USE IN MIGRAINE | PFIZER LTD (GB) | 1996-02-07 | — | — | EP | disclosed |
| WO-1994024127-A1 | INDOLE DERIVATIVES AS 5-H1-LIKE AGONISTS FOR USE IN MIGRAINE | PFIZER LIMITED (GB) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | HTT 2086/4885LMNA 4459/4885SMN1; SMN2 111/4885 |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | TK1, MKI67, CDKN1A | HTT 3544/4885LMNA 3416/4885SMN1; SMN2 3198/4885 |
| US-20070032487-A1 | Inhibitors of phosphatidylinositol 3-kinase | PIK3CA, PIP4K2C, PIP4K2B | HTT 4542/4885LMNA 2699/4885SMN1; SMN2 2425/4885 |
| US-20250352659-A1 | SELF-STABILIZING LINKER CONJUGATES | H1-0, MAPT, FCGRT | HTT 929/4885LMNA 2717/4885SMN1; SMN2 1197/4885 |
| US-12145913-B2 | Inhibition of Olig2 activity | POU2F2, POU2F1, PLP2 | HTT 2063/4885LMNA 4465/4885SMN1; SMN2 327/4885 |
| US-11242323-B2 | Inhibition of OLIG2 activity | POU2F2, ING2, PAX2 | HTT 2038/4885LMNA 4437/4885SMN1; SMN2 311/4885 |
| US-20130172349-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIP4K2C | HTT 4462/4885LMNA 2640/4885SMN1; SMN2 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.